Videos
Publicly traded Aerie Pharmaceuticals Inc. has two Rho kinase inhibitors, or ROCK inhibitors, in development, CEO Vicente Anido, Jr, PhD, reported Rhopressa which is in phase…
Read MoreONL Therapeutics Inc. is developing Met12, a small peptide inhibitor that uses a novel mechanism to attack Fas receptor apoptosis, which has a key role…
Read MoreKala Pharmaceutical Inc. is moving its proprietary Lotoprednol Etaobnate Mucus Penetrating Particle (LE-MPP) platform through a host of trials, Interim President and CBO Charlie McDermott…
Read MoreClinicians have few treatment options for dry AMD, but Translatum Medicus Inc., is working on an agent, TMi-018, for such an indication. President and CSO…
Read MorePanoptes Pharma GmhB is developing PP-001, a dihydroorotate dehydrogenase (DHODH) inhibitor for local treatments in ocular disease, Co-Founder and CEO Franz Obermayr, PhD, told the…
Read MoreModerator: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare…
Read MoreWaveTec Vision® Systems, Inc. is a privately-held ophthalmic medical device company and is the proven leader in intraoperative wavefront technology. The company is focused on…
Read MoreBarry Cheskin discusses PowerVision’s six month data on their pilot study and the beginning their CE mark study. Presenter: Barry Cheskin Barry Cheskin is Co-Founder,…
Read MoreFranz Obermayr gives a short overview of Panoptes Pharma founded only last year, covering only one of their developments: C0C01 for local treatment in ophthalmology. Presenter:…
Read MoreAmar Sawhney gives us an update on what’s going on in Ocular Therapeutix, showing us an in depth look at their product pipeline and what…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.